# PRF Technologies Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/PRF Technologies Ltd.).

## Overview

PRF Technologies Ltd. is a U.S.-listed company with two operating lines: a pharmaceutical development business focused on reformulating established therapeutics, and a software business built around its DeepSolar platform for AI-driven energy optimization. The company’s technology footprint includes the GridFeed and DeepSolar Predict offerings, which are used in renewable-energy forecasting, trading support, and performance optimization, alongside pharmaceutical programs using an extended-release drug-delivery system.

## Products & services

• Extended-release therapeutic reformulation programs
• OcuRing™-K ophthalmic drug program
• GridFeed™ renewable energy trading platform
• DeepSolar Predict™ AI forecasting engine
• Solar analytics and energy optimization software

- **Pharmaceutical development** (50%) — Programs to reformulate established therapeutics using proprietary drug-delivery systems.
- **Energy analytics software** (30%) — AI-based software for forecasting, monitoring, and optimizing energy use and production.
- **Energy trading decision support** (20%) — GridFeed tools for market participation, trading support, and revenue optimization.

- Extended-release therapeutic reformulation programs
- OcuRing™-K ophthalmic drug program
- GridFeed™ renewable energy trading platform
- DeepSolar Predict™ AI forecasting engine
- Solar analytics and energy optimization software

## Customers

PRF serves two very different customer groups: healthcare stakeholders interested in reformulated therapeutics and extended-release drug delivery, and renewable-energy participants needing forecasting and market decision tools. On the energy side, the company targets solar asset owners, operators, investors, traders, balancing responsible parties, and other market participants that need better visibility into production and price dynamics.

- **Solar asset owners and operators** (primary) — Buy forecasting, analytics, and optimization tools to improve solar performance and reduce imbalance costs.
- **Energy traders and market participants** (primary) — Use GridFeed for day-ahead and intraday trading decisions and revenue optimization.
- **Renewable-energy investors and advisors** (secondary) — Use DeepSolar analytics for technical due diligence, performance review, and risk assessment.
- **Healthcare and pharmaceutical partners** (secondary) — Support development and potential commercialization of reformulated therapeutic candidates.

- Solar asset owners seeking production and revenue optimization
- Energy traders using GridFeed for market participation decisions
- Operators and balancing responsible parties managing imbalance exposure
- Investors and diligence users assessing solar asset performance
- Healthcare stakeholders interested in prolonged post-surgical pain relief
- Partners and prospects evaluating commercial deployment of DeepSolar tools

## Geography

The company is U.S.-listed, but its reported operating footprint is international, with a disclosed base in Tel Aviv, Israel and commercial activity aimed at European energy markets. Its DeepSolar business is being presented to market participants in Europe, while the pharmaceutical programs are described through U.S.-based clinical development and reporting structures.

- **United States** (50%) — Clinical development and U.S. capital-market reporting are centered here.
- **Europe** (35%) — Commercial outreach for GridFeed is explicitly tied to European energy trading markets.
- **Middle East** (15%) — Company reporting and operational references indicate an Israeli presence.

- U.S.-listed company with global investor-facing reporting
- Operational base disclosed in Tel Aviv, Israel
- European market focus for GridFeed commercial outreach
- U.S.-based clinical development referenced for OcuRing™-K
- Cross-border structure adds currency and regulatory complexity

## Strategy

PRF is building a dual-track business that combines pharmaceutical reformulation with AI-enabled energy software, giving it exposure to both life sciences and renewable-energy workflows. Near term, the company is focused on advancing clinical development while commercializing DeepSolar through customer meetings, partnerships, and broader deployment of GridFeed in energy trading and optimization.

- **Advance OcuRing™-K and other healthcare programs** (short-term) — Clinical progress is needed to create optionality in the pharmaceutical pipeline and support long-term value creation.
- **Commercialize GridFeed in Europe** (short-term) — European energy trading is a concrete target market where the company can win early adopters for its AI tools.
- **Broaden DeepSolar from analytics into monetizable trading support** (medium-term) — Moving from forecasting to trading and revenue optimization expands the platform's value proposition and addressable use cases.

- Advance pharmaceutical candidates through clinical development
- Commercialize GridFeed with energy traders and asset owners
- Expand DeepSolar from forecasting into trading decision support
- Use partnerships to accelerate market access and prospecting
- Build a differentiated platform around AI, weather, and market data

## Risks

PRF faces the execution risks of a diversified early-stage company: clinical-development uncertainty in pharmaceuticals and adoption risk in a nascent software platform. It also has listing and financing risk, since management has disclosed the importance of meeting Nasdaq continued-listing standards and the business depends on external funding and partner traction.

- **Nasdaq continued listing compliance** [high] — The company disclosed risk of delisting if it fails minimum bid price, equity, or market value requirements.
- **Clinical development failure** [high] — Pharmaceutical candidates depend on trial execution and regulatory outcomes that can be delayed or negative.
- **Commercial adoption risk for DeepSolar** [medium] — The platform is still being introduced to customers and partners, so revenue conversion depends on market acceptance.
- **Funding and dilution risk** [high] — Early-stage development and commercialization typically require ongoing external capital.

- Clinical trial outcomes may not support drug development timelines
- GridFeed adoption depends on customer willingness to switch workflows
- Nasdaq listing compliance could affect liquidity and capital access
- Dual business model can stretch management and capital allocation
- Cross-border operations add regulatory and currency complexity

## Accounting

The company’s reporting includes judgment-heavy estimates typical of development-stage businesses, especially around income taxes, valuation allowances, and uncertain tax positions. Loss-per-share calculations also reflect preferred share, warrant, and option structures, which can materially affect per-share comparisons over time.

- **Deferred tax assets and valuation allowance** — Can materially change reported tax expense and equity
- **Uncertain tax positions** — Affects tax expense and contingency disclosures
- **Diluted loss per share** — Affects per-share comparability and dilution analysis

- Valuation allowance on deferred tax assets affects tax benefit recognition
- Uncertain tax positions may change reported tax expense
- Share-based awards and warrants affect diluted loss per share
- Development-stage estimates can drive asset and liability judgments

---

*Last updated: 2026-09-28T12:13:37.135468+00:00*